 <h1>Risedronate Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of risedronate include:</b> abdominal pain, arthralgia, and ostealgia. <b>Other side effects include:</b> bone fracture, arthropathy, and myalgia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to risedronate: oral tablet, oral tablet delayed release</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, risedronate may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking risedronate:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>skin rash</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach pain (severe)</li>
<li>belching</li>
<li>bone pain</li>
<li>cramping of the stomach</li>
<li>trouble swallowing</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Red, sore eyes</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bone, joint, or muscle pain, severe and occasionally incapacitating</li>
<li>chest pain</li>
<li>heartburn</li>
<li>pain or burning in the throat</li>
<li>sores, ulcers, or white spots on the lips or tongue or inside the mouth</li>
<li>vomiting</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking risedronate:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Confusion</li>
<li>convulsions</li>
<li>difficulty with breathing</li>
<li>irregular heartbeats</li>
<li>muscle cramps in the hands, arms, feet, legs, or face</li>
<li>numbness and tingling around the mouth, fingertips, or feet</li>
<li>shortness of breath</li>
<li>tremor</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of risedronate may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>cough or hoarseness</li>
<li>diarrhea</li>
<li>fever or chills</li>
<li>headache</li>
<li>joint pain</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>bladder pain</li>
<li>bloody or cloudy urine</li>
<li>blurred vision or change in vision</li>
<li>body aches or pains</li>
<li>congestion</li>
<li>constipation</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty with moving</li>
<li>dizziness</li>
<li>dry eyes</li>
<li>dryness or soreness of the throat</li>
<li>frequent urge to urinate</li>
<li>general feeling of discomfort or illness</li>
<li>indigestion</li>
<li>leg cramps</li>
<li>muscle pain or stiffness</li>
<li>nausea</li>
<li>nervousness</li>
<li>pain, swelling, or redness in the joints</li>
<li>pounding in the ears</li>
<li>ringing in the ears</li>
<li>runny nose</li>
<li>slow or fast heartbeat</li>
<li>stomach discomfort or upset</li>
<li>swelling of the feet or lower legs</li>
<li>tender swollen glands in the neck</li>
<li>voice changes</li>
<li>weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Fainting</li>
<li>fear</li>
<li>itching skin</li>
<li>loss of appetite</li>
<li>pale skin</li>
<li>passing of gas</li>
<li>redness, swelling, or soreness of the tongue</li>
<li>sneezing</li>
<li>stomach fullness</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>wheezing</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Eye pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>muscle pain</li>
<li>redness of the eye</li>
<li>sensitivity of the eye to light</li>
<li>skin blisters</li>
<li>tearing</li>
</ul><p>
<!-- end oral tablet, oral tablet delayed release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to risedronate: oral delayed release tablet, oral tablet</i></p><h3>General</h3><p>Abdominal and musculoskeletal pain were commonly reported adverse effects.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (up to 10.5%)</p>
<p><b>Common</b> (1% to 10%): Arrhythmia (2%) in men with osteoporosis</p>
<p><b>Frequency not reported</b>: Syncope, vasodilation<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (up to 12.9%), diarrhea (up to 10.8%), dyspepsia (up to 10.8%), nausea (up to 10.5%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, vomiting, abdominal upper pain, gastritis, gastroesophageal reflux disease, gastroenteritis</p>
<p><b>Uncommon</b> (0.1% to 1%): Duodenitis, glossitis</p>
<p><b>Rare</b> (less than 0.1%): Esophageal stricture</p>
<p><b>Postmarketing reports</b>: Esophagitis, esophageal or gastric ulcers<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (up to 11.1%)</p>
<p><b>Common</b> (1% to 10%): Nocturia (1.6%), cystitis, hemorrhoids, Hiatus hernia, urinary disorders, reproductive system and breast disorders<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 23.7%)</p>
<p><b>Common</b> (1% to 10%): Back pain, pain in extremity, musculoskeletal pain, bone pain, muscle spasms, myalgia, neck pain, arthritis, traumatic bone fracture, join disorder, leg cramps, myasthenia (1.6%), osteoarthritis, tendonitis</p>
<p><b>Rare</b> (less than 0.1%): Severe or incapacitating bone, join, or muscle pain; osteonecrosis of the jaw (ONJ); atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction)</p>
<p><b>Frequency not reported</b>: Muscle spasms<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Accidental injury (up to 16.9%), pain (up to 14.1%), flu syndrome (up to 11.6%)</p>
<p><b>Common</b> (1% to 10%): Tinnitus (1.6%), asthenia, peripheral edema, contusion, herpes zoster (1% to 2.6%), ear and labyrinth disorders, vertigo<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Bronchitis (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Influenza, upper respiratory infection, chest pain, sinusitis, rhinitis, pharyngitis, increased cough, apnea (1.6%)</p>
<p><b>Postmarketing reports</b>: Asthma exacerbations<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p>
<p><b>Frequency not reported</b>: Pruritus<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Elevated levels of parathyroid hormone (PTH), endocrine disorders<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia (1% to 2.6%), blood and lymphatic system disorders<sup>[Ref]</sup></p><h3>Hepatic</h3><p>In most of the postmarketing reported cases the patients were also treated with other products known to cause hepatic disorders.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Colitis (1.6%), hepatobiliary disorders</p>
<p><b>Rare</b> (less than 0.1%): Abnormal liver function test</p>
<p><b>Postmarketing reports</b>: Serious hepatic disorders<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Allergic reactions</p>
<p><b>Postmarketing reports</b>: Angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis, anaphylactic reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Immune system disorders<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Transient decreases from baseline in serum calcium (less than 1%) and serum phosphate (less than 3%) were observed within 6 months in patients in osteoporosis clinical trials treated with doses of 5 mg daily immediate-release.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased weight, hypocalcemia (1.6%), transient decreases from baseline of serum calcium and phosphate, hypercholesterolemia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, headache, insomnia, sciatica (0.6% to 2.3%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Cataract; amblyopia, corneal lesion and dry eye (1.6%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Iritis</p>
<p><b>Rare</b> (less than 0.1%): Eye inflammation including uveitis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Benign prostatic hyperplasia (5%) in men with osteoporosis; neoplasms benign, malignant and unspecified (including cysts and polyps)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, psychiatric disorders<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Nephrolithiasis (3%) in men with osteoporosis, renal disorders<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH. </p><p id="ref_2">2. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A "Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind, placebo-controlled study." J Clin Oncol 15 (1997): 955-62</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998): 779-89</p><p id="ref_5">5. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_6">6. Reginster JY, Colson F, Morlock G, Combe B, Ethgen D, Geusens P "Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study [published erratum appears in Arthritis Rheum 199 Jan;36(1):134]." Arthritis Rheum 35 (1992): 967-74</p><p id="ref_7">7. Taggart H,  Bolognese MA,  Lindsay R, et al. "Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials." Mayo Clin Proc 77 (2002): 262-70</p></div>
<div class="more-resources" id="moreResources">
<h2>More about risedronate</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>50 Reviews</li>
<li>Drug class: bisphosphonates</li>
<li>FDA Alerts (3)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Risedronate &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Actonel, Atelvia</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Prevention of Osteoporosis</li>
<li>Osteoporosis</li>
<li>Paget's Disease</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to risedronate: oral delayed release tablet, oral tablet</i></p><h3>General</h3><p>Abdominal and musculoskeletal pain were commonly reported adverse effects.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (up to 10.5%)</p><p><b>Common</b> (1% to 10%): Arrhythmia (2%) in men with osteoporosis</p><p><b>Frequency not reported</b>: Syncope, vasodilation<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (up to 12.9%), diarrhea (up to 10.8%), dyspepsia (up to 10.8%), nausea (up to 10.5%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, vomiting, abdominal upper pain, gastritis, gastroesophageal reflux disease, gastroenteritis</p><p><b>Uncommon</b> (0.1% to 1%): Duodenitis, glossitis</p><p><b>Rare</b> (less than 0.1%): Esophageal stricture</p><p><b>Postmarketing reports</b>: Esophagitis, esophageal or gastric ulcers<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (up to 11.1%)</p><p><b>Common</b> (1% to 10%): Nocturia (1.6%), cystitis, hemorrhoids, Hiatus hernia, urinary disorders, reproductive system and breast disorders<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 23.7%)</p><p><b>Common</b> (1% to 10%): Back pain, pain in extremity, musculoskeletal pain, bone pain, muscle spasms, myalgia, neck pain, arthritis, traumatic bone fracture, join disorder, leg cramps, myasthenia (1.6%), osteoarthritis, tendonitis</p><p><b>Rare</b> (less than 0.1%): Severe or incapacitating bone, join, or muscle pain; osteonecrosis of the jaw (ONJ); atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction)</p><p><b>Frequency not reported</b>: Muscle spasms<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Accidental injury (up to 16.9%), pain (up to 14.1%), flu syndrome (up to 11.6%)</p><p><b>Common</b> (1% to 10%): Tinnitus (1.6%), asthenia, peripheral edema, contusion, herpes zoster (1% to 2.6%), ear and labyrinth disorders, vertigo<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Bronchitis (up to 10%)</p><p><b>Common</b> (1% to 10%): Influenza, upper respiratory infection, chest pain, sinusitis, rhinitis, pharyngitis, increased cough, apnea (1.6%)</p><p><b>Postmarketing reports</b>: Asthma exacerbations<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p><p><b>Frequency not reported</b>: Pruritus<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Elevated levels of parathyroid hormone (PTH), endocrine disorders<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia (1% to 2.6%), blood and lymphatic system disorders<sup>[Ref]</sup></p><h3>Hepatic</h3><p>In most of the postmarketing reported cases the patients were also treated with other products known to cause hepatic disorders.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Colitis (1.6%), hepatobiliary disorders</p><p><b>Rare</b> (less than 0.1%): Abnormal liver function test</p><p><b>Postmarketing reports</b>: Serious hepatic disorders<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Allergic reactions</p><p><b>Postmarketing reports</b>: Angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis, anaphylactic reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Immune system disorders<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Transient decreases from baseline in serum calcium (less than 1%) and serum phosphate (less than 3%) were observed within 6 months in patients in osteoporosis clinical trials treated with doses of 5 mg daily immediate-release.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased weight, hypocalcemia (1.6%), transient decreases from baseline of serum calcium and phosphate, hypercholesterolemia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, headache, insomnia, sciatica (0.6% to 2.3%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Cataract; amblyopia, corneal lesion and dry eye (1.6%)</p><p><b>Uncommon</b> (0.1% to 1%): Iritis</p><p><b>Rare</b> (less than 0.1%): Eye inflammation including uveitis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Benign prostatic hyperplasia (5%) in men with osteoporosis; neoplasms benign, malignant and unspecified (including cysts and polyps)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, psychiatric disorders<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Nephrolithiasis (3%) in men with osteoporosis, renal disorders<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Actonel (risedronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH. </p><p id="ref_2">2. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A "Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind, placebo-controlled study." J Clin Oncol 15 (1997): 955-62</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998): 779-89</p><p id="ref_5">5. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_6">6. Reginster JY, Colson F, Morlock G, Combe B, Ethgen D, Geusens P "Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study [published erratum appears in Arthritis Rheum 199 Jan;36(1):134]." Arthritis Rheum 35 (1992): 967-74</p><p id="ref_7">7. Taggart H,  Bolognese MA,  Lindsay R, et al. "Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials." Mayo Clin Proc 77 (2002): 262-70</p><h2>More about risedronate</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>50 Reviews</li>
<li>Drug class: bisphosphonates</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Risedronate &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Prevention of Osteoporosis</li>
<li>Osteoporosis</li>
<li>Paget's Disease</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>